Lantheus director James Thrall sells $94,760 in stock

In a recent transaction, James H. Thrall, a director at Lantheus (NASDAQ:LNTH) Holdings, Inc. (NASDAQ:LNTH), sold 1,000 shares of the company's common stock. The shares were sold at a price of $94.76 each, totaling $94,760. Following this transaction, Thrall now holds 33,207 shares of Lantheus Holdings. The sale was conducted under a Rule 10b5-1 trading plan, which was adopted by Thrall on May 21, 2024.The $6.37 billion medical imaging company has demonstrated strong performance, with a 65.7% return over the past year and an EXCELLENT financial health rating according to InvestingPro analysis. Trading at a P/E of 14.8, InvestingPro's Fair Value analysis indicates the stock is currently undervalued. For comprehensive insider trading analysis and 8 additional key insights about LNTH, investors can access the full Pro Research Report on InvestingPro.

In other recent news, Lantheus Holdings has made significant strides in its financial restructuring, expanding its credit line from $350 million to $750 million and extending the maturity date from 2027 to 2029. The company reported an 18.4% increase in consolidated net revenue for Q3 2024, largely driven by the sales of PYLARIFY and DEFINITY. Lantheus has adjusted its full-year 2024 revenue guidance to a range of $1.51 billion to $1.52 billion, and its fully-diluted earnings per share forecast to between $6.65 and $6.70.

In terms of leadership, Dr. Jeff Humphrey is stepping down as Chief Medical (TASE:PMCN) Officer, with CEO Brian Markison and President Paul Blanchfield assuming interim responsibilities. Analyst firms including Goldman Sachs, TD Cowen, and Leerink Partners have provided their perspectives on Lantheus, with ratings ranging from Buy to Outperform and price targets between $110 and $143.

These developments highlight Lantheus Holdings' ongoing efforts to strengthen its financial position, operational efficiency, and market presence.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.